Biotech Startups

Apollo is a venture capital firm that invests in life-science and biotechnology startups, combining entrepreneurial expertise with deep scientific knowledge to support early-stage companies in drug development and personalized medicine.

8 investors

Aralez Bio produces noncanonical amino acids using biocatalysis, including compounds that add rigidity to peptide backbones and increase enzyme resistance. The company manufactures these at multi-kilogram scale for peptide and pharmaceutical applications.

8 investors

Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease. Its pipeline includes a candidate for Type 1 Myotonic Dystrophy (DM1), a form of muscular dystrophy.

8 investors

Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers. The company focuses on advancing DDR-based therapies through strategic partnerships.

8 investors

Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease. The company is a clinical-stage biotechnology firm focused on personalized neuron replacement therapies.

8 investors

Atomic Alchemy builds privately-owned nuclear reactors dedicated to radioisotope production, including Molybdenum-99 used in most nuclear medicine procedures. It aims to supply radiopharmaceutical materials for diagnostic imaging, biological tracers, and cancer treatments.

8 investors

Axiom Therapeutics runs a drug discovery platform for covalent inhibitors, applying machine learning to speed up physics-based simulations. The work is aimed at oncology research teams pursuing targets that have been difficult to drug.

8 investors

Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases. The company works across multiple therapeutic areas to advance precision medicine treatments at the molecular level.

8 investors

Bioptimus is an AI-first biotech company developing a universal AI foundation model that connects biology across scales, from molecules and cells to tissues and whole organisms, to support biomedical research and innovation. It applies machine learning to areas such as computational pathology, genomics, and drug discovery.

8 investors

Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. The therapies use modified blood stem cells to restore function of affected genes and offer potential cures rather than symptom management.

8 investors

Osteoboost is an FDA-cleared bone health solution designed for postmenopausal women with osteopenia. The company was founded by physicians, engineers, and entrepreneurs to address low bone mass and osteoporosis prevention through clinical innovation.

8 investors

BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

8 investors

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells. The company focuses on creating therapies that are more effective and easier to administer than existing antibody and cell therapy approaches.

8 investors

Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform. The company licenses foundational CRISPR-Cas9 intellectual property and advances drug candidates for patients with devastating diseases.

8 investors

Carrick Therapeutics is a biopharmaceutical company with a leadership team experienced in oncology drug development and commercialization. The company focuses on developing and advancing cancer treatments through clinical development and business development activities.

8 investors

Cellular Intelligence develops cell therapy treatments, specifically acquiring STEM-PD, a Phase 2-ready therapy for Parkinson's disease. The company focuses on cell fate engineering to design biological solutions for neurological diseases.

8 investors

Character Bio is a patient-driven therapeutics company that combines genomics, longitudinal clinical and imaging data, and machine learning to identify genetic drivers of disease progression and develop new treatments, with a focus on polygenic diseases. It builds deeply-phenotyped patient cohorts by partnering with patients, providers, and scientists to enable clinical genomic research.

8 investors

Circe develops a biotechnology platform that uses advanced gas transformation to produce carbon-negative molecules at scale for manufacturing. The company serves industrial manufacturers seeking to decarbonize production of high-performance products while securing supply chains.

8 investors

Cognition Therapeutics is a clinical-stage biotechnology company developing zervimesine (CT1812), an investigational once-daily oral small-molecule therapy designed to protect brain synapses by blocking toxic protein oligomers. It targets neurodegenerative diseases including dementia with Lewy bodies (DLB) and Alzheimer's disease.

8 investors

Compass Therapeutics uses proprietary antibody discovery platforms to generate and screen diverse panels of monoclonal and multispecific antibodies, aiming to identify synergistic therapeutic combinations. Its pipeline focuses on immuno-oncology therapies that bridge the innate and adaptive immune systems by targeting T cells, NK cells, and macrophages.

8 investors

Conception develops stem cell technology to create functional reproductive cells in the laboratory, enabling in-vitro gametogenesis as a solution for individuals facing biological and medical fertility barriers.

8 investors

Concerto Bio generates large-scale ecological datasets on microbial communities and uses them to develop microbe-based consumer health products for applications such as skincare, chronic disease, and nutrition. Its approach combines high-throughput experimental data generation with predictive modeling to make microbial communities engineerable.

8 investors

Correlia Biosystems, a UC Berkeley spinoff, develops microscale tools for rapid quantification of biomolecules from microliter-scale blood samples, aimed at generating large proteomic data sets for pharmaceutical companies. Its applications span next-generation proteomics research and point-of-care diagnostics.

8 investors

Embark Veterinary develops dog DNA tests and science-backed supplements for dog health and genetics. The company serves dog owners seeking genetic insights and nutritional products for their pets.

8 investors